Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 3/20 | 0.31 |
| ▸ | STK4 | Q13043 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | IDO1 | P14902 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6071815 | 0.93 | SMN1; SMN2 (0.34) | TDP1SMN1; SMN2MEN1ALDH1A1KMT2A | |
| SCHEMBL6071599 | 0.92 | TDP1 (0.32) | TDP1IRAK4 | |
| SCHEMBL6072213 | 0.92 | TDP1 (0.32) | TDP1IRAK4 | |
| SCHEMBL6072875 | 0.92 | KDM4E (0.36) | TDP1MEN1ALDH1A1KMT2APOLB | |
| Hydrochloric Acid SCHEMBL6072515 | 0.91 | TDP1 (0.32) | TDP1IRAK4 | |
| SCHEMBL6072205 | 0.91 | IRAK4 (0.33) | TDP1KMT2AIRAK4 | |
| SCHEMBL6071856 | 0.90 | CREBBP (0.39) | TDP1SMN1; SMN2MEN1ALDH1A1KMT2A | |
| SCHEMBL6071949 | 0.90 | HDAC1 (0.38) | SMN1; SMN2MEN1ALDH1A1KMT2APOLB | |
| SCHEMBL6071900 | 0.90 | TDP1 (0.32) | TDP1 | |
| SCHEMBL6072104 | 0.90 | FFAR4 (0.33) | TDP1IRAK4IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060106048-A1 | Furoisoquinoline derivative and use thereof | PASCALI, PETROS P. (CY) | 2006-05-18 | — | — | US | disclosed |
| EP-1541576-A1 | FUROISOQUINOLINE DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2005-06-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106048-A1 | Furoisoquinoline derivative and use thereof | PDE3B, PDE2A, PDE3A | TDP1 761/4885SMN1; SMN2 4490/4885MEN1 1942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.